Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin ointment versus placebo for secondarily infected traumatic lesions
2015-004903-22Phase 3
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondarily infected traumatic lesion (SITL) comparing Retapamulin ointment with Placebo ointment (2 arms). Primary endpoint: Clinical response at follow-up.
02
Drugs
retapamulin
03
Conditions
secondarily infected traumatic lesion (SITL)
Beyond the preview
Go deeper on 2015-004903-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004903-22.